Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Plasma cell 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 7Adenocarcinoma of Lung 5Neoplasms 4Neuroblastoma 3Neoplasm Metastasis 3Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Melanoma 2Granuloma, Plasma Cell 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Lymphoma, B-Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive Advanced Tumors 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21Standard of Care 20Sirolimus 20Azacitidine 20venetoclax 19Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × ceritinib × Clear all
NCT02186821 2021-04-08

SIGNATURE

Novartis

Phase 2 Terminated
47 enrolled 13 charts
LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Hematologic Neoplasms

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT02343679 2017-02-01

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Duke University

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡